GCM
MRNA icon

Graham Capital Management’s Moderna MRNA Stock Holding History

Graham Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
+4,473
New +$231K 0.01% 883
2025
Q4 		– Sell
-31,068
Closed -$802K – 1461
2025
Q3 		$802K Sell
31,068
-86,885
-74% -$2.42M 0.01% 449
2025
Q2 		$3.25M Buy
117,953
+105,717
+864% +$2.78M 0.05% 228
2025
Q1 		$347K Buy
+12,236
New +$434K 0.01% 940
2024
Q4 		– Sell
-10,991
Closed -$735K – 1386
2024
Q3 		$735K Buy
10,991
+1,874
+21% +$172K 0.01% 540
2024
Q2 		$1.08M Buy
9,117
+5,726
+169% +$725K 0.02% 397
2024
Q1 		$361K Sell
3,391
-487
-13% -$49.1K 0.01% 719
2023
Q4 		$386K Buy
+3,878
New +$326K 0.01% 663
2022
Q4 		– Sell
-3,837
Closed -$453K – 1218
2022
Q3 		$453K Buy
3,837
+1,853
+93% +$281K 0.02% 773
2022
Q2 		$283K Buy
+1,984
New +$284K 0.01% 849
2022
Q1 		– Sell
-1,577
Closed -$400K – 975
2021
Q4 		$400K Sell
1,577
-7,220
-82% -$2.11M 0.02% 225
2021
Q3 		$3.38M Buy
+8,797
New +$3.24M 0.17% 61

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Graham Capital Management's MRNA Position: Q2 2026 in Review

Graham Capital Management opened a new position in Moderna (MRNA) in Q2 2026: 4,473 shares worth $313K. The stake represents 0.01% of the portfolio and ranks #883 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in MRNA as recently as Q3 2025.

Graham Capital Management first reported a position in MRNA in Q3 2021 and has held it in 12 quarters since. The position peaked at $3.38M in Q3 2021. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Graham Capital Management held 4,473 shares of Moderna worth $313K as of Q2 2026.
  • Moderna was a new Graham Capital Management position in Q2 2026.
  • Moderna made up 0.01% of Graham Capital Management's portfolio in Q2 2026, its #883 holding.
  • Graham Capital Management first reported a position in Moderna in Q3 2021 and has held it in 12 quarters since.
  • Graham Capital Management's Moderna position peaked at $3.38M in Q3 2021.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.